These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 956809

  • 1. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD, Ruthven CR, Goodwin BL, Sandler M.
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE.
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [Abstract] [Full Text] [Related]

  • 3. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S, Falaschi P, Baldassarre M, D'Urso R, De Giorgio G, Rocco A, Agnoli A.
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [Abstract] [Full Text] [Related]

  • 4. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N, Kuzuya F, Mori K, Sakamoto N.
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
    Lieberman A, Estey E, Gopinathan G, Ohashi T, Sauter A, Goldstein M.
    Neurology; 1978 Sep; 28(9 Pt 1):964-8. PubMed ID: 567768
    [Abstract] [Full Text] [Related]

  • 6. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
    Mars H.
    Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
    [No Abstract] [Full Text] [Related]

  • 7. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
    Battistin L, Meneghetti G, Rigotti S, Saia A.
    Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
    [Abstract] [Full Text] [Related]

  • 8. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N, Sarre S, Ebinger G, Michotte Y.
    J Neural Transm (Vienna); 2001 Feb; 108(5):559-70. PubMed ID: 11459076
    [Abstract] [Full Text] [Related]

  • 9. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
    Bender DA, Earl CJ, Lees AJ.
    Clin Sci (Lond); 1979 Jan; 56(1):89-93. PubMed ID: 477187
    [Abstract] [Full Text] [Related]

  • 10. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P.
    Rev Prat; 1974 Mar 11; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
    Hanzal F.
    MMW Munch Med Wochenschr; 1976 May 14; 118(20):653-6. PubMed ID: 818540
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL, Rondot P, Cardon P.
    Therapie; 1977 May 14; 32(2):161-72. PubMed ID: 898124
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
    Sweet RD, McDowell FH, Wasterlain CG, Stern PH.
    Arch Neurol; 1975 Aug 14; 32(8):560-3. PubMed ID: 1156214
    [Abstract] [Full Text] [Related]

  • 17. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL, Ringel SP, Shenker DM.
    J Neurol Neurosurg Psychiatry; 1971 Dec 14; 34(6):682-6. PubMed ID: 5158783
    [Abstract] [Full Text] [Related]

  • 18. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M, Keller HH, Pieri L, Kettler R, Haefely WE.
    Experientia; 1984 Nov 15; 40(11):1165-72. PubMed ID: 6437857
    [Abstract] [Full Text] [Related]

  • 19. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
    Shen H, Kannari K, Yamato H, Arai A, Matsunaga M.
    Tohoku J Exp Med; 2003 Mar 15; 199(3):149-59. PubMed ID: 12703659
    [Abstract] [Full Text] [Related]

  • 20. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F, Mentasti M, Riederer P, Birkmayer W.
    Wien Klin Wochenschr; 1979 May 11; 91(10):332-7. PubMed ID: 452602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.